1Intensive Care Unit, Department of Anesthesiology, Jikei University School of Medicine, Tokyo, Japan. 2Department of Internal Medicine, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan. 3Division of Intensive Care Medicine, Hyogo College of Medicine, Hyogo, Japan. 4Intensive Care Unit, Department of Anesthesiology, Saitama Medical Center, Jichi Medical University, Saitama, Japan. 5Department of Emergency and Critical Care, Showa University Fujigaoka Hospital, Kanagawa, Japan. 6Department of Emergency Medicine, Asahi General Hospital, Chiba, Japan. 7Department of Nephrology and Hypertension, St. Marianna University School of Medicine, Kanagawa, Japan. 8Intensive Care Unit, Department of Emergency and Critical Care Medicine, Japanese Red Cross Musashino Hospital, Tokyo, Japan. 9Intensive Care Unit, Osaka University Hospital, Osaka, Japan. 10Division of Intensive Care, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan. 11Department of Emergency, Kanto Rosai Hospital, Kanagawa, Japan.
Crit Care Med. 2013 Nov;41(11):2584-91. doi: 10.1097/CCM.0b013e318298622e.
To study the hospital mortality of patients with severe acute kidney injury treated with low-intensity continuous renal replacement therapy.
Multicenter retrospective observational study (Japanese Society for Physicians and Trainees in Intensive Care), combined with previously conducted multinational prospective observational study (Beginning and Ending Supportive Therapy).
Fourteen Japanese ICUs in 12 tertiary hospitals (Japanese Society for Physicians and Trainees in Intensive Care) and 54 ICUs in 23 countries (Beginning and Ending Supportive Therapy).
Consecutive adult patients with severe acute kidney injury requiring continuous renal replacement therapy admitted to the participating ICUs in 2010 (Japanese Society for Physicians and Trainees in Intensive Care, n = 343) and 2001 (Beginning and Ending Supportive Therapy Beginning and Ending Supportive Therapy, n = 1,006).
None.
Patient characteristics, variables at continuous renal replacement therapy initiation, continuous renal replacement therapy settings, and outcomes (ICU and hospital mortality and renal replacement therapy requirement at hospital discharge) were collected. Continuous renal replacement therapy intensity was arbitrarily classified into seven subclasses: less than 10, 10-15, 15-20, 20-25, 25-30, 30-35, and more than 35 mL/kg/hr. Multivariable logistic regression analysis was conducted to investigate risk factors for hospital mortality. The continuous renal replacement therapy dose in the Japanese Society for Physicians and Trainees in Intensive Care database was less than half of the Beginning and Ending Supportive Therapy database (800 mL/hr vs 2,000 mL/hr, p < 0.001). Even after adjusting for the body weight and dilution factor, continuous renal replacement therapy intensity was statistically different (14.3 mL/kg/hr vs 20.4 mL/kg/hr, p < 0.001). Patients in the Japanese Society for Physicians and Trainees in Intensive Care database had a lower ICU mortality (46.1% vs 55.3%, p = 0.003) and hospital mortality (58.6% vs 64.2%, p = 0.070) compared with patients in the Beginning and Ending Supportive Therapy database. In multivariable regression analysis after combining the two databases, no continuous renal replacement therapy intensity subclasses were found to be statistically different from the reference intensity (20-25 mL/kg/hr). Several sensitivity analyses (patients with sepsis, patients from Western countries in the Beginning and Ending Supportive Therapy database) confirmed no intensity-outcome relationship.
Continuous renal replacement therapy at a mean intensity of 14.3 mL/kg/hr did not have worse outcome compared with 20-25 mL/kg/hr of continuous renal replacement therapy, currently considered the standard intensity. However, our study is insufficient to support the use of low-intensity continuous renal replacement therapy, and more studies are needed to confirm our findings.
研究采用低强度持续肾脏替代疗法治疗的严重急性肾损伤患者的院内死亡率。
多中心回顾性观察性研究(日本医师和重症监护培训生学会),结合之前进行的多国前瞻性观察性研究(开始和结束支持性治疗)。
12 家三级医院的 14 个日本重症监护病房(日本医师和重症监护培训生学会)和 23 个国家的 54 个重症监护病房(开始和结束支持性治疗开始和结束支持性治疗)。
2010 年(日本医师和重症监护培训生学会,n = 343)和 2001 年(开始和结束支持性治疗开始和结束支持性治疗,n = 1006)入住参与重症监护病房的需要连续肾脏替代治疗的连续肾脏替代治疗的成年严重急性肾损伤患者。
无。
收集患者特征、连续肾脏替代治疗开始时的变量、连续肾脏替代治疗设置以及结局(重症监护病房和医院死亡率以及出院时的肾脏替代治疗需求)。连续肾脏替代治疗强度被任意分为七个亚类:<10、10-15、15-20、20-25、25-30、30-35 和>35 mL/kg/hr。进行多变量逻辑回归分析以调查医院死亡率的危险因素。日本医师和重症监护培训生学会数据库中的连续肾脏替代治疗剂量不到开始和结束支持性治疗数据库的一半(800 mL/hr 与 2000 mL/hr,p < 0.001)。即使在调整体重和稀释因子后,连续肾脏替代治疗强度仍存在统计学差异(14.3 mL/kg/hr 与 20.4 mL/kg/hr,p < 0.001)。与开始和结束支持性治疗数据库中的患者相比,日本医师和重症监护培训生学会数据库中的患者 ICU 死亡率(46.1%对 55.3%,p = 0.003)和医院死亡率(58.6%对 64.2%,p = 0.070)较低。在合并两个数据库的多变量回归分析中,没有发现任何连续肾脏替代治疗强度亚类与参考强度(20-25 mL/kg/hr)存在统计学差异。几项敏感性分析(开始和结束支持性治疗数据库中的败血症患者、西方国家患者)证实了没有强度-结局关系。
与目前认为的标准强度(20-25 mL/kg/hr)相比,平均强度为 14.3 mL/kg/hr 的连续肾脏替代治疗并未导致更差的结局。然而,我们的研究不足以支持低强度连续肾脏替代治疗的使用,需要更多的研究来证实我们的发现。